- Home
- BKKT vs CHRS Comparison
BKKT vs CHRS Comparison
Compare BKKT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKKT | CHRS |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | 48 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.5M | 296.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | BKKT | CHRS |
|---|---|---|
| Price | $8.41 | $1.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $21.50 | $5.51 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $73.08 |
| Revenue Next Year | $261.39 | $30.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.87 | $0.72 |
| 52 Week High | $49.79 | $2.62 |
Technical Indicators
Market Signals| Indicator | BKKT | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.29 | 39.51 |
| Support Level | $7.94 | $1.55 |
| Resistance Level | $10.29 | $1.80 |
| Average True Range (ATR) | 0.76 | 0.11 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 23.24 | 1.83 |
Price Performance
Historical ComparisonAbout BKKT Bakkt Holdings Inc.
Bakkt Inc builds digital financial infrastructure designed to support institutional participation in the digital asset economy. The company platform is built to accommodate various digital assets and offers its clients the flexibility to build a product that aligns with its vision and customers' needs. Its services include Bakkt Markets, Bakkt Agent, Bakkt Global.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.